With rapid market growth and significant technological advantages, molecular diagnostics has become the “golden track” in the field of in vitro diagnostics. This technology utilizes molecular biology methods to detect structural or expression changes in DNA, RNA, and proteins within patients, thereby providing evidence for disease prevention, diagnosis, and precision treatment. Compared to traditional diagnostic methods such as biochemical, immunological, and microbiological assays, molecular diagnostics offers advantages in speed, sensitivity, specificity, and comprehensive information, now thriving in the golden age of gene chips and high-throughput testing. Through technological iterations, molecular diagnostics has been widely applied in non-invasive prenatal testing (NIPT), hereditary tumor screening, personalized cancer treatment guidance, and other areas, advancing the concept of “preventive medicine”. According to industry reports, infectious diseases, eugenics, sexually transmitted diseases, tumors/cancers, and genetic disorders are the primary application areas. Among these, NIPT has become the mainstream eugenics screening method due to its non-invasive nature, safety, short testing cycle, and high accuracy. Driven by national policies promoting fertility, China’s molecular diagnostics market for eugenics is expected to exceed ¥10 billion in the future.
Coronary heart disease remains one of the leading causes of death worldwide. Studies in healthy populations have demonstrated that every 1 mg/dL increase in plasma high-density lipoprotein cholesterol (HDL-C) levels is associated with a 2%-3% reduction in coronary heart disease incidence. Specific HDL subfractions can serve as biomarkers for coronary heart disease, enabling early identification of high-risk populations and providing novel strategies for its prevention and treatment.
In China, the population incidence of preeclampsia ranges from 5.6% to 9.4%. It is defined as a pregnancy-specific disorder typically occurring after 20 weeks of gestation, characterized by two main clinical features: (1) New-onset hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg), (2) At least one new-onset complication (proteinuria, placental dysfunction, or other maternal organ dysfunction).
Through pathogenic gene identification and prenatal diagnosis, high-risk fetuses can be early detected, providing families with genetic counseling and decision-making support. Current research demonstrates that gene sequencing technologies exhibit high efficiency and accuracy in pathogenic gene identification and prenatal diagnosis, serving as critical tools for preventing and managing these conditions.
All Contents ©2025 AAAR. All Rights Reserved.
